National Center for Research and Development, Poland
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women ≥18 years of age.
Patients with one of the following types of cancer: non-small cell lung cancer, melanoma.
Patients with informed consent to participate in the study.
Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
The applied immunotherapy should be the first or second line of treatment.
You may not be if
Patients who are unable to understand, read and / or sign informed consent.
Patients who can not collect stools.
Patients with fecal transplant.
The applied immunotherapy is not the first or second line of treatment.
Clareo Health | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
